The penetration of active ingredients from topically applied anti-inflammatory pharmaceutical products into tissues below the skin is the basis of their therapeutic efficacy. There is still controversy as to whether these agents are capable of direct penetration by diffusion through the tissues or whether redistribution in the systemic circulation is responsible for their tissue deposition below the application site. Methods The extent of direct penetration of salicylate from commercial ester and salt formulations into the dermal and subcutaneous tissue of human volunteers was determined using the technique of cutaneous microdialysis. We also examined differences in the extent of hydrolysis of the methylester of salicylate applied topically in human volunteers and in vitro skin diffusion cells using full-thickness skin and epidermal membranes. Results The present study showed that whilst significant levels of salicylate could be detected in the dermis and subcutaneous tissue of volunteers treated with the methylsalicylate formulation, negligible levels of salicylate were seen following application of the triethanolamine salicylate formulation. The tissue levels of salicylate from the methylsalicylate formulation were approx. 30-fold higher than the plasma concentrations. Conclusion The absorption and tissue concentration profiles for the commercial methylsalicylate formulation are indicative of direct tissue penetration and not solely redistribution by the systemic blood supply.
Introduction destructive nature, their inability to give multiple time samples from the same site and their likelihood of resultant Despite its evolved barrier properties, the skin is an important route of entry into the body for many topically applied temporary or permanent scarring. One of the most popular over-the-counter groups of solutes. Topical pharmaceutical products targeted locally below the site of skin application are assumed to exert their topical agents are the salicylate-containing anti-inflammatory formulations (most commonly methylsalicylate (MeSA) and effect by penetration of the active ingredient directly into deeper tissues, though there is still controversy over whether triethanolamine salicylate (TEASA)) recommended for use in a wide range of painful or inflammatory conditions in many agents are in fact removed by the dermal blood supply before they reach their desired site of action. In a study by muscle and joints and as passive pre-sports muscle warm ups. It has been shown that first-pass metabolism exists in Dawson et al. [1] synovial fluid concentrations of the antiinflammatory agent biphenylacetic acid (felbinac) in the skin with esterases rapidly hydrolysing salicylate esters to release the active salicylate in both the epidermis and dermis arthritic patients following application of 3g of a 3% gel were found to be similar in treated and control knees and [3] . A number of classical bioavailability studies in humans have examined the kinetic profiles of topical salicylate were only approximately half that seen in plasma, suggesting that no direct penetration of the drug into the treated knee formulations and determined the effects of various factors such as site of application, multiple dosing and heat and joint had occurred. More traditional methods for the assessment of efficacy of topical products in human volunteers exercise based on analysis of plasma levels and urinary excretion. Roberts et al. [4] found that the urinary excretion rely predominantly on kinetic analysis of plasma, urinary excretion and faecal drug and/or metabolite profiles [2] .
of salicylate and metabolites from a MeSA formulation in humans was site dependent, highest when applied to the Other techniques such as analysis of drug remaining on the skin, determination of pharmacodynamic end points, tissue abdomen rather than identical surface areas on the forearm or lower limb. A more recent study by Morra et al. [5] , biopsy, suction blister fluid analysis and skin windows have also been used though the latter direct assessments of tissue showed that the absorption rate of topical MeSA also increased with repeated application and that salicylate bioavailability was significantly higher from this formulation and heat exposure has been shown to increase the plasma mately 15×15 mm pieces and mounted, stratum corneum uppermost, in Franz-type glass diffusion cells, surface area concentrations and urinary excretion of topical MeSA by up to three times, highlighting the importance of blood flow 1.3cm 2 . Human epidermal membranes were also prepared from breast skin using the heat separation method and on absorption kinetics from topical sites [6] . None of the above studies, however, addressed the local tissue concenmounted in the diffusion cells over fine cotton gauze to provide support. Skin samples (full-thickness or epidermal trations of active ingredient following application of the topical formulations, the presence or absence of which forms membranes) were allowed to equilibrate for 1 h in a water bath at 35°C over receptor fluid (degassed, 20% ethanol580% the basis of their therapeutic efficacy. In the present study we used cutaneous microdialysis to determine the direct distilled water) continuously stirred with magnetic fleas. At time zero 1g of topical commercial formulation containing local penetration of topically applied nonsteroidal antiinflammatory formulations containing esters or salts of 20% MeSA, 7% glycol salicylate (GSA) or 10% TEASA ( Figure 1 ) was placed onto the stratum corneum side of the salicylate.
Cutaneous microdialysis is a relatively new technique skin and receptor fluid removed and replaced with fresh solution at 1, 2, 3, 4, 5, 6, 8, 22 and 24 h. Due to the which allows the continuous monitoring of endogenous or exogenous solutes in the interstitial fluid of dermal or limited number of skin samples harvested from the donor, and to avoid complication of comparison across human subcutaneous tissue with minimal tissue destruction. The technique involves the placement of small perfused probes samples, only full-thickness in vitro membranes were studied for the GSA formulation. Samples were assayed for parent into the skin at given depths (e.g. dermis or subcutaneous tissue). The ends of these probes incorporate a small dialysis salicylate ester and salicylate by h.p.l.c. At the end of each study, diffusion cells were dismantled, skin samples cleared membrane window across which solutes can exchange from the interstitial fluid. Since the first report of microdialysis of remaining formulation and wiped with alcohol swabs, the stratum corneum side stripped once with Scotch Tape TM sampling in dermis [7] , the technique has been used successfully in human volunteers to study the endogenous and sample area exposed to formulation excised and placed into preweighed vials. Epidermis or 100 mg of finely cutaneous release of histamine in response to various topical stimuli [8] and the penetration of a number of topically chopped full-thickness skin were minced with scissors in 380 ml acetonitrile to which 100 ml of distilled water and applied organic solvents (e.g. ethanol, isopropanol) [9] . Microdialysis is also gaining use in the characterisation of 20 ml of 35% phosphoric acid was added. Samples were then vortexed, sonicated on ice for 30 s, centrifuged and the transdermal transport [10] , to date examining drugs such as nicotine and lignocaine [11, 12] with normal saline at 1.6 ml min −1 using a portable syringe 24 h from each formulation are shown in Table 1 . Salicylic acid was freely soluble in the receptor phase and MeSA was driver (MS16A, Graseby Medical, Gold Coast, Australia). Following 1 h probe equilibration, commercial topical soluble to over 500 mg ml −1 , which was well in excess of drug concentrations determined throughout the in vitro salicylate formulations (as used in vitro) containing 20% MeSA, 7% GSA or 10% TEASA ( Figure 1 ) were applied to studies, suggesting that sink conditions were adequate. Permeability as flux of active ingredients from the methyl a 16cm 2 area of skin over the probe tips but at least 10 mm from covered probe insertion points. Dialysate samples were ester and TEA salt formulations of salicylate through human epidermal membranes were approximately three-fold faster collected at 30-60 min intervals for up to 360 min. In two subjects application of TEASA was started 24 h before probe than through full-thickness skin. The ratio of MeSA to salicylate from the MeSA formulation appeared to remain insertion. Subjects applied a liberal amount of formulation to the test area at 2-3 h intervals, except during the night, relatively constant at around 351 for both full-thickness skin and epidermal membranes. In full-thickness skin studies no in order to achieve maximal concentrations at the test site. At the end of the sampling period, blood samples were free salicylate was detected in the receptor phase of cells treated with the GSA formulation. taken from the vein in the treated arm in each volunteer. Blood was centrifuged, plasma protein precipitated by 151
Comparison of the amount of drug remaining in fullthickness skin and epidermal membrane samples at the end dilution in acetonitrile, recentrifuged and assayed for salicylates. Formulations were reapplied every 2 h during of each of the studies following application of MeSA and TEASA formulations (Table 1) showed that the epidermis the sampling period to mimic their intended clinical use. Samples were assayed for parent salicylate ester and salicylate appeared to be the major site for deposition of salicylate from the salt and to some extent that generated from the by h.p.l.c.
Following removal of the probe from the volunteer at methylester salicylate formulation. Dermal deposits of salicylates were determined by subtraction of the amount of drug the end of the study, recovery of salicylate and/or salicylate ester was determined in vitro from known concentrations in determined in the epidermal samples from that found in full-thickness skin, and accounting for equivalent fraction of 2% bovine serum albumin buffer at pH 7.4. Recovery was used to adjust dialysate concentrations to those estimated to epidermis weight (0.0103±0.004 g/cell) in the full-thickness samples (0.2808±0.096 g/cell). It was estimated that over be present just outside the probe tip dialysis membrane.
99.9% of the salicylate present in full-thickness skin samples treated with the TEASA formulation could be accounted Sample analysis for in the epidermis. The penetration of the methylester into the dermis of full-thickness skin samples in vitro was High performance liquid chromatography was used for the analysis of salicylate and salicylate esters in samples from estimated to be four orders of magnitude greater than from the salt formulation. both in vitro and in vivo studies. Mobile phase consisted of 50550 acetonitrile50.05 m potassium phosphate buffer at pH 3, flow rates used were 1.0 and 1.2 ml min −1 , injection In vivo volume was 50 ml (in vitro study) and 10 ml (in vivo study) onto a m-Bondapack C18 (3.9×300 mm) column (Waters, Recovery of salicylate into probes was 30.7±3.5%, mean±s.e.mean, with all reported dialysate levels adjusted Millipore, Australia) with detection by either u.v. (salicylate and salicylate esters)(l 237 nm) or fluorescence (in vivo by this amount to allow estimation of corresponding tissue levels immediately outside the membrane. Significant salicylate)(Excitation l 295 nm, emission l 400 nm) over a 15 min run time. Two Shimadzu hardware systems amounts of salicylate were found in the dialysate from both dermal and subcutaneous probes in volunteers receiving the (Shimadzu Oceania Pty Ltd, Australia) were used consisting of (i) a LC-6AD pump, SIL-6B autoinjector and a SPD-6A methylsalicylate and glycolsalicylate formulations, but not the TEASA formulation ( Figure 2 ). The cumulative amount UV detector and (ii) a 10AD pump, SIL 9A autoinjector and a RF-10AXL fluorescence detector.
of salicylate present in the dermis estimated from dialysate following approximately 5 h of application was over 80-fold higher in volunteers treated with the 20% MeSA compared Data analysis with the 10% TEASA formulation. Salicylate dialysate to plasma ratios (Table 2) showed that estimated tissue concenSlopes from linear regression of plots of receptor fluid concentration vs time from in vitro diffusion cells were used trations were substantially higher than that in the circulating blood following application of salicylate ester formulations to calculate the permeability as flux of salicylate and salicylate esters through human skin.
but not the TEASA salt. The time course of salicylate penetration into dialysate was fairly rapid for the ester formulations. Salicylate from Results the MeSA formulation could be detected within 1 h of application and continued to rise rapidly over the first In vitro 30-90 min then appeared to plateau, with reapplication of the dose at 2 h showing a repeat in this pattern of increase Substantial amounts of salicylate and its parent esters penetrated human skin in vitro. The permeability as flux (Figure 2a ). In the two volunteers receiving glycolsalicylate, dermal levels were apparent at 60-90 min following applicalculated from the cumulative amount vs time plots together with the relative amount of total salicylate or parent ester cation and appeared to plateau after 2 h at around 1.72 mg ml −1 , even following reapplication of the formupenetrating full-thickness skin or epidermal membranes in (Figure 2b ). The levels of salicylate in similar differences in esterase activity between viable and non-viable skin without any corresponding change in the both dermal and subcutaneous probes were low and near the limit of detection of the fluorescence assay (50 ng ml −1 ) percutaneous absorption rates of MeSA or benzyl alcohol in guinea pig skin. The group also suggested that the rate of following application of the TEASA formulation in all four volunteers, including the two volunteers predosed for 24 h skin permeation of MeSA was determined by diffusion through the stratum corneum and that the primary metabwith the formulation.
In all of the analyses of in vivo samples only salicylate olism seems to occur in the viable tissues beneath the stratum corneum after the rate of permeation has been could be detected in the dialysate and plasma of volunteers, with no evidence of either the parent MeSA or GSA ester determined.
The epidermal membranes produced, as expected, higher applied in the formulation. In order to increase the limit of detection of the h.p.l.c. assay to 10 ng ml −1 , dialysate permeability as flux than the full-thickness skin samples in vitro. However, the ratio of fluxes of the salicylates samples from volunteers were pooled for each individual and five times the volume injected, however there were still absorbed into the receptor phase from the methylester compared with the TEASA salt formulation remained no detectable parent salicylate ester peaks.
relatively constant across the two membranes, a ratio of 1.6 for epidermal membranes and 1.8 for full-thickness skin Discussion samples. These data suggest that the dermis constitutes a similar barrier to the diffusion of active ingredients from The human skin permeability as flux generated by the in vitro studies showed that substantial amounts of salicylate both formulations as, other than the extra time taken to diffuse across this unstirred layer in vitro, no significant penetrated skin by diffusion alone from all of the formulations tested, particularly the GSA gel. The significant amounts of changes to the absorption profiles from either formulation were observed. This finding also suggests that the TEASA parent salicylate ester penetrating into the receptor fluid from MeSA and GSA formulations suggested a relatively formulation has approximately twice the bioequivalency of the MeSA cream. The TEASA cream contained around one low rate of hydrolysis of these solutes by skin esterases. However, the human breast skin used had been stored quarter the amount of salicylate by weight as the MeSA formulation, as the TEA accounts for half of its weight, and frozen at −20°C prior to the study and therefore the activity of esterases within the tissue would not have been an equivalent ratio active ingredient flux of 4 would have been predicted. The in vivo microdialysis data, however, equivalent to that seen in vivo. Due to high esterase activity in living skin [3] , the levels of salicylate esters determined suggested a lack of correlation between the permeability of salicylate from the TEASA formulation based on the in vitro in receptor fluid could be assumed to exist primarily as salicylate when extrapolating the observed permeabilities to findings. The in vitro permeability as flux for the active salicylate in the TEA salt formulation was approximately the in vivo situation. In vivo human microdialysis confirmed the high esterase activity in viable skin as no trace of parent 60% of that observed for the combination of MeSA and salicylate from the MeSA formulation. Based on this findester from the MeSA and GSA formulations were observed, though their ability to diffuse as the parent moiety had been ing, it could be assumed that levels of salicylate following in vivo application of the TEASA formulation would be proven in vitro. Figure 3 summarises the difference in levels
The in vitro finding of high deposition of salicylate from the TEASA formulation in the epidermis compared with the MeSA product may have some bearing on the lack of correlation between the in vitro and in vivo results. It is possible that in vivo salicylate in the epidermis is not being released as quickly as in vitro due to differences in sink conditions or stronger binding to viable or other tissue constituents. These effects would result in a low and prolonged release of salicylate into the systemic circulation or tissue surrounding the microdialysis probe at concentrations near or below the level of detection of the assays employed in the present study. The ratio of total active ingredients (MeSA plus salicylate) estimated to be present in the dermis from the TEASA compared with MeSA formulation were extremely low in both studies, with values of 0.003 and 0.012 in vitro and in vivo respectively. The combination of this finding with the observed in vitro permeability as flux suggests that whilst salicylate from the TEASA formulation is strongly associated with the epidermis its release and diffusion across the dermis in vitro must be fairly rapid, resulting in a reasonably high accumulation in the receptor and subsequent calculated flux. A differential penetration of salicylic acid and salicylate salts into multilayer membrane systems and the human horny layer in vitro was noted by Neubert et al. [18] . This group found that whilst salicylic acid penetrated rapidly into all membranes the sodium and choline salts of salicylate accumulated in the first membrane. Pardo et al. [19] suggested that, following application of a physostigmine ion-pair of salicylate, ionization of ion-pairs at the pH of hydrated stratum corneum occured immediately after partitioning into the membrane and subsequent diffusion of the ionized species across the membrane. In the present study it could also be anticipated that the TEASA ion-pair would dissociate upon partitioning importance of systemic blood levels in accounting for salicylate concentrations in underlying tissues after dermal application was related to (i) the depth of the tissue, (ii) the approximately 60% of those seen with the MeSA formulation. In reality this figure was only 1%. Pilot studies using time of application, and (iii) the tissue blood flow. Deep tissue penetration by direct diffusion or other means was a diethylamine salicylate salt topical formulation also failed to show any significant amounts of salicylate in dermal likely to be most evident in the more superficial tissues immediately after topical application. The tissue concentissues within 3 h of application (unpublished data). In the present study the plasma levels of salicylate were very low trations tend to fall exponentially with depth due to the tissue clearance of salicylate by perfusing blood in each tissue and not significantly different in the volunteers receiving these two formulations on separate occasions, and therefore the salicylate may penetrate into. The time dependency of systemic blood determined tissue concentrations depends on a higher clearance by the dermal blood did not appear to be a likely explanation for this apparent lack of in vivo tissue the accumulation of sufficient salicylate into the systemic circulation from the blood perfusing each tissue and the penetration of salicylate from the TEASA formulation. In a recent clinical study examining the plasma levels and urinary relative penetration rate of salicylate into deeper tissues [14] . The importance of the third determinant of tissue blood excretion of salicylate and its metabolites following application of a TEASA and MeSA formulation to the thigh of flow is evident in the perfused limb work of Cross & Roberts [20] , vasoconstriction work of Singh & Roberts healthy volunteers, it was shown that salicylate could not be detected in the plasma following TEASA application and
[21] and in the tissue depth-salicylate concentration relationships in alive and sacrificed animals [15] . This work shows that recovery of metabolites in the urine was significantly lower for this formulation than following application of that an increase in dermal and other tissue clearance as a consequence of an increase in tissue blood flow is reflected MeSA which also gave detectable plasma levels within the first hour of application [5] .
by a decrease in underlying tissue levels below an application The present differences in MeSA and ionised salicylate penetration in vivo are no doubt greater than in vitro for this reason. Singh & Roberts [24] suggested that tissue binding was a significant determinant of deep tissue penetration in sacrificed animals i.e. equivalent to the in vitro studies here. The differential concentrations of salicylate in the dermis after MeSA and TEASA application is consistent with this difference. Interestingly, Singh & Roberts [24] found that protein binding was not a determinant of the penetration of solutes into deeper tissues in vivo. It is likely in practice that, as reported in animals [14, 15] and in man [1, 22] salicylate in deeper tissues below the superficial muscle after topical application may be mainly determined by salicylate from systemic recirculation.
The present study clearly shows, however, that direct local tissue penetration of active ingredient was achieved with the MeSA and GSA formulations. The high tis-
In vivo
In vitro solutes into deeper tissues following clearance by the dermal blood supply was occurring then tissue5plasma ratios would have been expected to be unity or below, as observed in site. These observations account for the apparent discrepancy between the present results and those of Dawson et al. [1] the case of the TEASA formulation which showed no evidence of direct tissue penetration following topical and Radermacher et al. [22] . In both the latter studies, drug levels were studied in very deep tissues (synovial fluid) at a application.
The study also highlights the importance of the technique reasonable time after topical application (8 h and 4 days respectively) in humans with rheumatoid arthritis likely to of microdialysis in enabling continuous monitoring of tissue levels of topically applied solutes for the determination of be associated with increased tissue perfusion around the knee and below the topical application site. Characterisation of esterase and alcohol dehydrogenase activity
